MediGene AG Appoints Dr. Frank Mathias as new Chief Executive Officer

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Martinsried/Munich, 29. April 2009. MediGene AG (Frankfurt: MDG,
Prime Standard, TecDAX) announced today that Dr. Peter Heinrich,
Chief Executive Officer, has resigned from his position as member of
the Executive Board with immediate effect. The Supervisory Board has
accepted the resignation with great regret.

"On behalf of the MediGene Supervisory Board, I would like to thank
Dr Peter Heinrich for his long time and successful leadership as
Chief Executive Officer of the company. As a co-founder, he
essentially shaped the company from the beginning. Due to his
entrepreneurial achievements, MediGene today is an internationally
acknowledged biotech company with subsidiaries in the UK and the USA
and is listed in the German stock index TecDAX. The supervisory Board
expresses its heartfelt thankfulness for his achievements and wishes
him all the best for his future path of life", says Prof Dr
Ernst-Ludwig Winnacker, Chairman of the Supervisory Board of MediGene
AG.

As successor, Dr. Frank Mathias has been appointed by the Supervisory
Board. He has joined MediGene a year ago as Chief Operating Officer
and Executive Board Member for Marketing, Sales and Business
Development and has been responsible for the ongoing partnering
process for the cancer drug candidate EndoTAG-1. The pharmacist with
PhD has around 20 years' experience in the pharma and biotech
industry, among others as General Manager of Amgen GmbH, the German
subsidiary of one of the world-leading biotechnology company Amgen
Inc.

Dr. Mathias studied pharmacy at Paris VI University, taking his PhD
in 1991. He embarked on his career in industry in 1988 as
International Product Manager with Hoechst AG, Frankfurt, then in
1990 joined Albert-Roussel Pharma GmbH in Wiesbaden, first as a
Pharmaceuticals Officer, then as a Product Group Manager and as
Deputy Head of Marketing. In 1995 Dr. Mathias launched the
Anti-Infectives Marketing Department at Hoechst Pharma in Frankfurt
before moving as Head of Marketing to Servier Deutschland GmbH in
Munich and taking over as General Manager there in 1996. In 2002 he
moved as Head of Marketing to Amgen GmbH, Munich, the company he led
successfully as General Manager since 2003. In April 2008, he joined
the Executive Board of MediGene AG.

"I would like to express my thanks for the trust put in me by to the
Supervisory Board. I accept the new challenge with great pleasure and
a deep confidence that MediGene AG will continue to develop
successfully. MediGene has an excellent team of employees and I look
very much forward to working with them furthermore", says Dr Frank
Mathias, the new Chief Executive Officer of MediGene AG.

This press release contains forward-looking statements that involve
risks and uncertainties. The forward-looking statements contained
herein represent the judgment of MediGene as of the date of this
release. These forward-looking statements are no guarantees for
future performance, and the forward-looking events discussed in this
press release may not occur. MediGene disclaims any intent or
obligation to update any of these forward-looking statements.
MediGeneTM is a trademark of MediGene AG. This trademark may be held
or licensed for specific countries.

- ends -

MediGene AG is a publicly listed (Frankfurt: MDG, Prime Standard,
TecDAX) biotechnology company located in Martinsried/Munich, Germany,
with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the
first German biotech company to have drugs on the market, which are
being distributed by partner companies and has several drug
candidates in clinical development, two of which provide significant
sales potential. In addition, the company has numerous projects in
research and pre-clinical development and possesses innovative
platform technologies. MediGene focuses on the research and
development of novel drugs for the treatment of cancer and autoimmune
diseases

Contact MediGene AG
E-mail: investor@medigene.com
Fax: +49 - 89 - 85 65 - 2920
Julia Hofmann / Dr. Nadja Wolf, Public Relations, Tel.: +49 - 89 - 85
65 - 3324
Dr. Georg Dönges, Investor Relations, Tel.: +49 - 89 - 85 65 - 2946

--- End of Message ---

MediGene AG
Lochhamer Strasse 11 Martinsried / München Germany

WKN:
502090; ISIN: DE0005020903 ;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Bayerische Börse München,
Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Niedersächsische Börse zu Hannover,
Regulierter Markt in Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2009. All rights reserved.